Eledon Pharmaceuticals Receives FDA Orphan Drug Designation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 10 2026
0mins
Source: seekingalpha
- FDA Orphan Drug Designation: Eledon Pharmaceuticals' lead candidate, tegoprubart, has received Orphan Drug designation from the FDA, which is expected to provide a crucial treatment option for preventing allograft rejection in liver transplantation, enhancing the company's competitive position in the biotech sector.
- Market Opportunity Assessment: CEO David-Alexandre Gros stated that based on encouraging preclinical evidence, liver transplantation represents a significant incremental market opportunity for tegoprubart, potentially driving future revenue growth for the company.
- Clinical Trial Plans: The company anticipates initiating an investigator-sponsored trial later this year to further validate the efficacy and safety of the antibody therapy, aiming to expedite the product's market entry.
- Regulatory Incentives: The FDA's Orphan Drug designation offers Eledon multiple regulatory advantages, including tax credits for clinical trial costs and waivers for marketing application user fees, along with up to seven years of U.S. marketing exclusivity, significantly enhancing the company's commercial outlook.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELDN
Wall Street analysts forecast ELDN stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.930
Low
4.00
Averages
7.75
High
10.00
Current: 3.930
Low
4.00
Averages
7.75
High
10.00
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Completes GMP Master Cell Bank for Anti-Aging Therapy
- Cell Bank Milestone: On May 20, 2026, Avaí Bio and Austrianova announced the completion of a GMP-grade Master Cell Bank, marking a significant advancement in their clinical trial path and expected to accelerate the development of anti-aging therapies.
- Viral Testing Protocol: The Master Cell Bank will undergo independent testing by a top-tier third-party provider to ensure the absence of pathogens and contaminants, aligning with FDA regulatory expectations to guarantee product safety and efficacy.
- Subsequent Production Plans: Following successful testing, a Working Cell Bank will be derived from the Master Cell Bank to manufacture the final Cell-in-a-Box clinical product, providing strong support for Avaí Bio's competitive position in the anti-aging market.
- Anti-Aging Protein Research: The restoration of the α-Klotho protein is closely linked to the treatment of various age-related diseases, and Avaí Bio's research not only advances cell therapy but may also offer new solutions to address health issues associated with aging.
See More
NewcelX Completes Successful FDA Meeting, Advancing Diabetes Treatment
- FDA Meeting Outcome: NewcelX successfully completed its Type B Pre-IND meeting with the FDA, receiving constructive feedback on the clinical trial pathway for NCEL-101, marking a significant milestone towards a potential functional cure for type 1 diabetes.
- Increased Development Confidence: CEO Ronen Twito stated that the FDA's feedback has strengthened the company's confidence in its development strategy for NCEL-101, indicating a commitment to expedite the therapy into clinical trials to meet urgent patient needs.
- Combination Therapy Potential: Eledon Pharmaceuticals' CEO Dr. David-Alexandre Gros highlighted that the combination of NCEL-101 with their anti-CD40L monoclonal antibody, tegoprubart, aims to achieve durable graft survival and function, potentially offering a scalable treatment option for individuals with type 1 diabetes.
- Clinical Experience Support: With over 100 transplant recipients having used tegoprubart, important safety and immunological insights have been gained, supporting the advancement of NCEL-101 and indicating its potential in clinical applications.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Natera Partners with Eledon for Kidney Transplant Trial Using Prospera Test
- Partnership Agreement: Natera and Eledon have entered into a partnership to utilize Natera's Prospera test in Eledon's planned Phase 3 trial for the kidney transplant drug tegoprurbart, marking a strategic collaboration in the field of cell-free DNA testing.
- Market Reaction: Eledon Pharmaceuticals' shares rose 5.06% to $4.1605 in pre-market trading on Nasdaq, reflecting positive market sentiment towards the partnership, following a 0.25% increase in Wednesday's regular session.
- Trial Scale: The trial aims to enroll approximately 600 kidney transplant recipients across over 100 centers globally, set to commence in late 2026, indicating Eledon's expansion plans and market potential in the kidney transplant sector.
- Drug Background: Tegoprurbart is an anti-CD40L antibody being tested as an alternative to standard immunosuppressive drugs like tacrolimus, which carry toxicity risks, and this collaboration will aid in advancing the clinical validation of new therapies.
See More
Eledon Pharmaceuticals Reports Positive Long-Term Data for Tegoprubart in Kidney Transplantation
- Clinical Trial Results: Eledon Pharmaceuticals' BESTOW trial shows that at 18 months, Tegoprubart-treated patients had a mean estimated glomerular filtration rate (eGFR) of 74 mL/min/1.73 m², significantly higher than the 61 mL/min/1.73 m² in the Tacrolimus group, indicating its potential advantage in kidney transplant patients.
- Patient Survival Rates: In the BESTOW study, 96% of patients treated with Tegoprubart entered the long-term extension study compared to 86% in the Tacrolimus group, suggesting better long-term survival rates for Tegoprubart, which may influence future treatment choices.
- Safety Analysis: The BESTOW long-term extension study revealed that central nervous system and kidney-related adverse events were more frequent in the Tacrolimus group than in the Tegoprubart group, highlighting Tegoprubart's potential safety advantages that could attract more clinical applications.
- Future Development Plans: Eledon plans to initiate Phase 3 clinical development of Tegoprubart by late 2026, with cash and cash equivalents totaling $111.1 million as of March 31, 2026, demonstrating its financial capability to advance research and development.
See More
Eledon Reports Long-Term Data on Tegoprubart in Kidney Transplantation
- Significant Kidney Function Improvement: At 18 months, the mean eGFR for patients treated with Tegoprubart was 74 mL/min/1.73 m², showing a statistically significant advantage of approximately 12 mL/min/1.73 m² over the 61 mL/min/1.73 m² in the Tacrolimus group, indicating its potential to redefine standards in transplant immunomodulation.
- Zero Rejection Events: No biopsy-proven acute rejection (BPAR) events were observed in Tegoprubart-treated patients after six months, compared to seven events (approximately 9.4%) in the Tacrolimus arm, highlighting Tegoprubart's advantage in reducing rejection risks and potentially improving long-term transplant outcomes.
- Improved Patient-Reported Outcomes: At 52 weeks, Tegoprubart-treated patients reported significantly lower symptom burden on two validated measures compared to those on Tacrolimus, indicating enhanced quality of life, which is crucial for meeting the long-term needs of kidney transplant recipients.
- Next Steps in Development: Eledon plans to initiate Phase 3 clinical development of Tegoprubart by late 2026, with the primary endpoint being non-inferiority to Tacrolimus at 52 weeks, leveraging key insights from the BESTOW trial to further validate its clinical advantages.
See More
Avaí Bio Completes GMP Master Cell Bank for Anti-Aging Therapy
- Cell Bank Milestone: On May 20, 2026, Avaí Bio and Austrianova announced the completion of a GMP-grade Master Cell Bank, marking a significant advancement in their clinical trial path and expected to accelerate the development of anti-aging therapies.
- Viral Testing Protocol: The Master Cell Bank will undergo independent testing by a top-tier third-party provider to ensure the absence of pathogens and contaminants, aligning with FDA regulatory expectations to guarantee product safety and efficacy.
- Subsequent Production Plans: Following successful testing, a Working Cell Bank will be derived from the Master Cell Bank to manufacture the final Cell-in-a-Box clinical product, providing strong support for Avaí Bio's competitive position in the anti-aging market.
- Anti-Aging Protein Research: The restoration of the α-Klotho protein is closely linked to the treatment of various age-related diseases, and Avaí Bio's research not only advances cell therapy but may also offer new solutions to address health issues associated with aging.
See More
NewcelX Completes Successful FDA Meeting, Advancing Diabetes Treatment
- FDA Meeting Outcome: NewcelX successfully completed its Type B Pre-IND meeting with the FDA, receiving constructive feedback on the clinical trial pathway for NCEL-101, marking a significant milestone towards a potential functional cure for type 1 diabetes.
- Increased Development Confidence: CEO Ronen Twito stated that the FDA's feedback has strengthened the company's confidence in its development strategy for NCEL-101, indicating a commitment to expedite the therapy into clinical trials to meet urgent patient needs.
- Combination Therapy Potential: Eledon Pharmaceuticals' CEO Dr. David-Alexandre Gros highlighted that the combination of NCEL-101 with their anti-CD40L monoclonal antibody, tegoprubart, aims to achieve durable graft survival and function, potentially offering a scalable treatment option for individuals with type 1 diabetes.
- Clinical Experience Support: With over 100 transplant recipients having used tegoprubart, important safety and immunological insights have been gained, supporting the advancement of NCEL-101 and indicating its potential in clinical applications.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
Natera Partners with Eledon for Kidney Transplant Trial Using Prospera Test
- Partnership Agreement: Natera and Eledon have entered into a partnership to utilize Natera's Prospera test in Eledon's planned Phase 3 trial for the kidney transplant drug tegoprurbart, marking a strategic collaboration in the field of cell-free DNA testing.
- Market Reaction: Eledon Pharmaceuticals' shares rose 5.06% to $4.1605 in pre-market trading on Nasdaq, reflecting positive market sentiment towards the partnership, following a 0.25% increase in Wednesday's regular session.
- Trial Scale: The trial aims to enroll approximately 600 kidney transplant recipients across over 100 centers globally, set to commence in late 2026, indicating Eledon's expansion plans and market potential in the kidney transplant sector.
- Drug Background: Tegoprurbart is an anti-CD40L antibody being tested as an alternative to standard immunosuppressive drugs like tacrolimus, which carry toxicity risks, and this collaboration will aid in advancing the clinical validation of new therapies.
See More
Eledon Pharmaceuticals Reports Positive Long-Term Data for Tegoprubart in Kidney Transplantation
- Clinical Trial Results: Eledon Pharmaceuticals' BESTOW trial shows that at 18 months, Tegoprubart-treated patients had a mean estimated glomerular filtration rate (eGFR) of 74 mL/min/1.73 m², significantly higher than the 61 mL/min/1.73 m² in the Tacrolimus group, indicating its potential advantage in kidney transplant patients.
- Patient Survival Rates: In the BESTOW study, 96% of patients treated with Tegoprubart entered the long-term extension study compared to 86% in the Tacrolimus group, suggesting better long-term survival rates for Tegoprubart, which may influence future treatment choices.
- Safety Analysis: The BESTOW long-term extension study revealed that central nervous system and kidney-related adverse events were more frequent in the Tacrolimus group than in the Tegoprubart group, highlighting Tegoprubart's potential safety advantages that could attract more clinical applications.
- Future Development Plans: Eledon plans to initiate Phase 3 clinical development of Tegoprubart by late 2026, with cash and cash equivalents totaling $111.1 million as of March 31, 2026, demonstrating its financial capability to advance research and development.
See More
Eledon Reports Long-Term Data on Tegoprubart in Kidney Transplantation
- Significant Kidney Function Improvement: At 18 months, the mean eGFR for patients treated with Tegoprubart was 74 mL/min/1.73 m², showing a statistically significant advantage of approximately 12 mL/min/1.73 m² over the 61 mL/min/1.73 m² in the Tacrolimus group, indicating its potential to redefine standards in transplant immunomodulation.
- Zero Rejection Events: No biopsy-proven acute rejection (BPAR) events were observed in Tegoprubart-treated patients after six months, compared to seven events (approximately 9.4%) in the Tacrolimus arm, highlighting Tegoprubart's advantage in reducing rejection risks and potentially improving long-term transplant outcomes.
- Improved Patient-Reported Outcomes: At 52 weeks, Tegoprubart-treated patients reported significantly lower symptom burden on two validated measures compared to those on Tacrolimus, indicating enhanced quality of life, which is crucial for meeting the long-term needs of kidney transplant recipients.
- Next Steps in Development: Eledon plans to initiate Phase 3 clinical development of Tegoprubart by late 2026, with the primary endpoint being non-inferiority to Tacrolimus at 52 weeks, leveraging key insights from the BESTOW trial to further validate its clinical advantages.
See More
